Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts

Leukemia volume 18, pages 1539–1540 (2004)Cite this article

TO THE EDITOR

Philadelphia (Ph)-chromosome-positive chronic myeloid leukemia (CML) with the e19a2 rearrangement encoding p230 protein is a rare disease with varying clinical presentation and course.1, 2, 3, 4, 5 The e19a2 rearrangement was initially reported to be present as neutrophilic CML with a benign clinical course, but it has been reported with increasing frequency in patients with typical CML, and some of these patients exhibit an aggressive clinical course.1, 2, 3, 4, 5 Although several therapeutic modalities have been attempted, there is no consistent data on the treatment of CML patients with the e19a2 rearrangement.1, 2, 3, 4, 5 Since imatinib (Glivec®) induces a substantial cytogenetic response in chronic-phase (CP) CML after α-interferon failure, imatinib is used in all phases of CML at present.6 However, most of the patients reported in previous studies were CML with p210 or p190 protein.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Saglio G, Guerrasio A, Rosso C, Zaccaria A, Tassinari A, Serra A et al. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1990; 76: 1819–1824.

    CAS  PubMed  Google Scholar 

  2. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996; 88: 2410–2414.

    CAS  PubMed  Google Scholar 

  3. Briz M, Vilches C, Cabrera R, Fores R, Fernandez MN . Typical chronic myelogenous leukemia with e19a2 junction BCR/ABL transcript. Blood 1997; 90: 5024–5025.

    CAS  PubMed  Google Scholar 

  4. How GF, Tan LT, Lim LC . Chronic myeloid leukemia with e19a2 (c3a2) BCR/ABL fusion junction – is it truly a benign disease? Leukemia 1998; 12: 1166–1167.

    Article  CAS  PubMed  Google Scholar 

  5. Polak J, Koza V, Cetkovsky P, Haskovec C . An accelerated-phase CML patient with e19a2 junction of BCR/ABL gene – the first case of transplanted CML with micro bcr. Bone Marrow Transplant 2000; 25: 1109–1110.

    Article  CAS  PubMed  Google Scholar 

  6. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.

    Article  CAS  PubMed  Google Scholar 

  7. Kim YJ, Kim DW, Lee S, Kim HJ, Kim YL, Hwang JY et al. Comprehensive comparison of FISH, RT-PCR, and RQ-PCR for monitoring the bcr-abl gene after hematopoietic stem cell transplantation in CML. Eur J Haematol 2002; 68: 272–280.

    Article  CAS  PubMed  Google Scholar 

  8. Cross NC, Melo JV, Feng L, Goldman JM . An optimized multiplex polymerase chain reaction for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186–189.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by a grant from the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (01-PJ10-PG6-01GN16-0005).

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Chonnam National University Medical School, Gwangju, South Korea

    J-J Lee & H-J Kim

  2. Genome Research Center for Hematopoietic Diseases, Chonnam National University Hospital, Gwangju, South Korea

    J-J Lee & H-J Kim

  3. Molecular Hematology Laboratory, Catholic Hematopoietic Stem Cell Transplantation Center, The Catholic University of Korea, Seoul, South Korea

    Y-J Kim, S Lee, J-Y Hwang, Y-L Kim & D-W Kim

Authors
  1. J-J Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H-J Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y-J Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J-Y Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y-L Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D-W Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D-W Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, JJ., Kim, HJ., Kim, YJ. et al. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts. Leukemia 18, 1539–1540 (2004). https://doi.org/10.1038/sj.leu.2403454

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403454

This article is cited by

Search

Advanced search

Quick links